• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

印度糖尿病治疗的药物处方模式与成本分析:一项内分泌科实践的审计

Drug Prescription Patterns and Cost Analysis of Diabetes Therapy in India: Audit of an Endocrine Practice.

作者信息

Singla Rajiv, Bindra Jatin, Singla Ankush, Gupta Yashdeep, Kalra Sanjay

机构信息

Department of Endocrinology, Kalpavriksh Healthcare, Dwarka, India.

Department of Health Informatics, Kalpavriksh Healthcare, Dwarka, India.

出版信息

Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):40-45. doi: 10.4103/ijem.IJEM_646_18.

DOI:10.4103/ijem.IJEM_646_18
PMID:31016151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6446683/
Abstract

AIMS

The aim of this study was to analyze the current trend in the use of antidiabetes as well as other drugs for comorbidities along the duration of diabetes. The study also aimed to analyze the direct drug cost to patients.

SETTINGS AND DESIGN

Retrospective cross-sectional study.

SUBJECTS AND METHODS

Data captured in clinic electronic medical records of an endocrine practice was analyzed.

STATISTICAL ANALYSIS USED

Data was analyzed descriptively using machine learning codes on python platform.

RESULTS

Records of 489 people who attended the clinic during the 6-month period were retrieved. Data of 403 people with diabetes were analyzed after exclusion of incomplete data. Use of antidiabetic drug increased from 1.44 (0.78) [mean (standard deviation)] in people with a duration of diabetes <5 years to 3.18 (1.05) in people with 20+ years of diabetes. The mean number of antidiabetic drug usage seems to plateau at 15 years of diabetes. About 46% of people with 20+ years of diabetes required insulin therapy. Prescription patterns involving a combination of different drug classes in patients were also analyzed. The cost of diabetes therapy increases linearly along the duration of diabetes.

CONCLUSION

This study provides valuable insights on temporal prescription patterns of antidiabetic drugs from an endocrine practice. Metformin remains the most preferred drug across the entire duration of diabetes. Dipeptidyl peptidase-4 inhibitors seem to be fast catching up with sulfonylureas as a second-line treatment after metformin. After 20 years or more of diabetes duration, 46% people would require insulin for glycemic control.

摘要

目的

本研究旨在分析糖尿病病程中抗糖尿病药物以及用于治疗合并症的其他药物的使用现状趋势。该研究还旨在分析患者的直接药物成本。

设置与设计

回顾性横断面研究。

研究对象与方法

分析了一家内分泌诊所临床电子病历中记录的数据。

所用统计分析方法

在Python平台上使用机器学习代码对数据进行描述性分析。

结果

检索到了6个月期间到该诊所就诊的489人的记录。排除不完整数据后,对403名糖尿病患者的数据进行了分析。糖尿病病程<5年的患者抗糖尿病药物的使用量从1.44(0.78)[均值(标准差)]增加到糖尿病病程≥20年的患者的3.18(1.05)。抗糖尿病药物的平均使用量在糖尿病病程15年时似乎趋于平稳。糖尿病病程≥20年的患者中约46%需要胰岛素治疗。还分析了患者中涉及不同药物类别组合的处方模式。糖尿病治疗成本随糖尿病病程呈线性增加。

结论

本研究为内分泌诊所抗糖尿病药物的时间处方模式提供了有价值的见解。二甲双胍在糖尿病的整个病程中仍然是最常用的药物。二肽基肽酶-4抑制剂似乎正在迅速赶上磺脲类药物,成为二甲双胍后的二线治疗药物。糖尿病病程达到20年或更长时间后,46%的患者需要胰岛素来控制血糖。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/b872cd010ec3/IJEM-23-40-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/e0529df2dfb1/IJEM-23-40-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/259e04715c0d/IJEM-23-40-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/45a40f42faf8/IJEM-23-40-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/6156baa35ac9/IJEM-23-40-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/b872cd010ec3/IJEM-23-40-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/e0529df2dfb1/IJEM-23-40-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/259e04715c0d/IJEM-23-40-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/45a40f42faf8/IJEM-23-40-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/6156baa35ac9/IJEM-23-40-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05d/6446683/b872cd010ec3/IJEM-23-40-g005.jpg

相似文献

1
Drug Prescription Patterns and Cost Analysis of Diabetes Therapy in India: Audit of an Endocrine Practice.印度糖尿病治疗的药物处方模式与成本分析:一项内分泌科实践的审计
Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):40-45. doi: 10.4103/ijem.IJEM_646_18.
2
Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.美国抗糖尿病药物使用的长期趋势:新诊断为 2 型糖尿病患者的真实世界证据。
Diabetes Care. 2018 Jan;41(1):69-78. doi: 10.2337/dc17-1414. Epub 2017 Nov 6.
3
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.瑞格列奈:对其在2型糖尿病治疗中应用的药物经济学综述
Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005.
4
Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000-2019.基于 2000-2019 年电子健康记录的通用数据模型评估的 2 型糖尿病治疗模式。
J Korean Med Sci. 2021 Sep 13;36(36):e230. doi: 10.3346/jkms.2021.36.e230.
5
Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.二甲双胍联合二肽基肽酶-4抑制剂与二甲双胍联合磺脲类药物治疗2型糖尿病的成本效益分析
BMC Health Serv Res. 2018 Feb 1;18(1):78. doi: 10.1186/s12913-018-2860-0.
6
Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.在日本工作年龄段的2型糖尿病患者中,二肽基肽酶-4抑制剂与双胍类作为一线抗高血糖药物的有效性和药物成本比较。
J Eval Clin Pract. 2020 Feb;26(1):299-307. doi: 10.1111/jep.13171. Epub 2019 Jun 3.
7
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.二肽基肽酶-4抑制剂治疗2型糖尿病的成本效益
Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y.
8
Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan.2005 年至 2014 年台湾地区抗糖尿病药物治疗趋势。
J Formos Med Assoc. 2019 Nov;118 Suppl 2:S74-S82. doi: 10.1016/j.jfma.2019.06.001. Epub 2019 Jun 25.
9
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.初诊糖尿病患者的药物起始模式:质量和成本影响。
Am J Med. 2012 Mar;125(3):302.e1-7. doi: 10.1016/j.amjmed.2011.07.033.
10
Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes.初诊年龄较轻的 2 型糖尿病患者二线口服降糖药治疗结局。
Diabetes Res Clin Pract. 2021 Jul;177:108928. doi: 10.1016/j.diabres.2021.108928. Epub 2021 Jun 24.

引用本文的文献

1
Metformin for the Treatment of Type 2 Diabetes in Asian Adults: A Systematic Review.二甲双胍用于治疗亚洲成年人2型糖尿病:一项系统评价
Diabetes Metab Syndr Obes. 2025 Mar 26;18:873-904. doi: 10.2147/DMSO.S479889. eCollection 2025.
2
Usefulness of Indian Diabetes Risk Score in Predicting Treatment-Induced Hyperglycemia in Women Undergoing Adjuvant Chemotherapy for Breast Cancer.印度糖尿病风险评分在预测接受乳腺癌辅助化疗的女性治疗诱导的高血糖中的效用。
South Asian J Cancer. 2023 Oct 13;14(1):4-14. doi: 10.1055/s-0043-1775805. eCollection 2025 Jan.
3
Which antidiabetic drugs do patients of T2DM prefer in India and why? A discrete choice experiment.

本文引用的文献

1
Temporal Change in Profile of Association between Diabetes, Obesity, and Age of Onset in Urban India: A Brief Report and Review of Literature.印度城市地区糖尿病、肥胖与发病年龄之间关联特征的时间变化:简要报告及文献综述
Indian J Endocrinol Metab. 2018 May-Jun;22(3):429-432. doi: 10.4103/ijem.IJEM_601_17.
2
Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: Do Indian households face distress health financing?印度住院治疗的特定疾病自付费用和灾难性卫生支出:印度家庭面临困境性卫生筹资吗?
PLoS One. 2018 May 10;13(5):e0196106. doi: 10.1371/journal.pone.0196106. eCollection 2018.
3
在印度,2型糖尿病患者更喜欢哪些抗糖尿病药物,原因是什么?一项离散选择实验。
J Family Med Prim Care. 2024 Nov;13(11):5090-5100. doi: 10.4103/jfmpc.jfmpc_605_24. Epub 2024 Nov 18.
4
Parietal Cell Antibodies in Type 1 Diabetes Mellitus and Its Implications for Iron Deficiency: A Tertiary Centre Experience from North India.1型糖尿病中的壁细胞抗体及其与缺铁的关系:来自印度北部一家三级中心的经验
Indian J Endocrinol Metab. 2024 Sep-Oct;28(5):536-541. doi: 10.4103/ijem.ijem_176_24. Epub 2024 Nov 8.
5
Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population.与印度人群中非胰岛素类抗糖尿病药物相关的药物遗传学变异的全景。
BMJ Open Diabetes Res Care. 2024 Mar 12;12(2):e003769. doi: 10.1136/bmjdrc-2023-003769.
6
Prevention of Type 1 Diabetes: Current Perspective.1型糖尿病的预防:当前观点
Indian J Endocrinol Metab. 2023 Jul-Aug;27(4):277-285. doi: 10.4103/ijem.ijem_78_23. Epub 2023 Aug 28.
7
Prescription pattern analysis of Type 2 Diabetes Mellitus: a cross-sectional study in Isfahan, Iran.2型糖尿病的处方模式分析:伊朗伊斯法罕的一项横断面研究。
BioData Min. 2023 Oct 20;16(1):29. doi: 10.1186/s13040-023-00344-y.
8
The LongitudinAl Nationwide stuDy on Management And Real-world outComes of diabetes in India over 3 years (LANDMARC trial).跨越 3 年的印度糖尿病管理与真实世界结局的纵向全国研究(LANDMARC 试验)。
Endocrinol Diabetes Metab. 2023 Sep;6(5):e422. doi: 10.1002/edm2.422. Epub 2023 Jul 1.
9
Investigation of treatment satisfaction and health-related quality of life after add-on to metformin-based therapy in patients with type 2 diabetes.在二甲双胍为基础的治疗方案上加用药物治疗 2 型糖尿病患者的治疗满意度和健康相关生活质量的调查。
Front Public Health. 2023 Apr 11;11:1152284. doi: 10.3389/fpubh.2023.1152284. eCollection 2023.
10
Prescribing pattern of anti-diabetic drugs and adherence to the American Diabetes Association's (ADA) 2021 treatment guidelines among patients of type 2 diabetes mellitus: A cross-sectional study.2型糖尿病患者抗糖尿病药物的处方模式及对美国糖尿病协会(ADA)2021年治疗指南的依从性:一项横断面研究。
J Family Med Prim Care. 2022 Oct;11(10):6159-6164. doi: 10.4103/jfmpc.jfmpc_458_22. Epub 2022 Oct 31.
Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study.
英国2型糖尿病的成本与治疗途径:一项策划群组研究
Diabetes Ther. 2017 Oct;8(5):1031-1045. doi: 10.1007/s13300-017-0296-x. Epub 2017 Sep 6.
4
Assessment of cost of illness for diabetic patients in South Indian tertiary care hospital.南印度三级护理医院糖尿病患者疾病成本评估。
J Pharm Bioallied Sci. 2016 Oct-Dec;8(4):314-320. doi: 10.4103/0975-7406.199336.
5
Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study.2007 - 2013年加泰罗尼亚地区2型糖尿病患者在基层医疗中心的血糖控制及抗糖尿病治疗趋势:一项基于人群的研究
BMJ Open. 2016 Oct 5;6(10):e012463. doi: 10.1136/bmjopen-2016-012463.
6
Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study.2000年至2013年基层医疗中2型糖尿病的发病率、患病率及处方趋势:一项回顾性队列研究。
BMJ Open. 2016 Jan 13;6(1):e010210. doi: 10.1136/bmjopen-2015-010210.
7
High burden of prediabetes and diabetes in three large cities in South Asia: The Center for cArdio-metabolic Risk Reduction in South Asia (CARRS) Study.南亚三个大城市的糖尿病前期和糖尿病高负担:南亚心血管代谢风险降低中心(CARRS)研究
Diabetes Res Clin Pract. 2015 Nov;110(2):172-82. doi: 10.1016/j.diabres.2015.09.005. Epub 2015 Sep 25.
8
The economic burden of diabetes in India: a review of the literature.印度糖尿病的经济负担:文献综述
Global Health. 2014 Dec 2;10:80. doi: 10.1186/s12992-014-0080-x.
9
Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.糖尿病患者口服降糖药物的初始选择:一项以患者为中心的比较有效性研究。
JAMA Intern Med. 2014 Dec;174(12):1955-62. doi: 10.1001/jamainternmed.2014.5294.
10
Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients.糖尿病患者中抗糖尿病药物维持最佳血糖水平的处方模式及疗效
J Basic Clin Pharm. 2014 Jun;5(3):79-83. doi: 10.4103/0976-0105.139731.